1034 related articles for article (PubMed ID: 11801559)
41. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
42. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
[TBL] [Abstract][Full Text] [Related]
43. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases.
Jentoft M; Giannini C; Rossi S; Mota R; Jenkins RB; Rodriguez FJ
Am J Surg Pathol; 2011 Jun; 35(6):845-52. PubMed ID: 21552114
[TBL] [Abstract][Full Text] [Related]
44. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
[TBL] [Abstract][Full Text] [Related]
45. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
46. [Towards a molecular classification of gliomas].
Hoang-Xuan K; Idbaih A; Mokhtari K; Sanson M
Bull Cancer; 2005 Apr; 92(4):310-6. PubMed ID: 15888387
[TBL] [Abstract][Full Text] [Related]
47. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
[TBL] [Abstract][Full Text] [Related]
48. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
[TBL] [Abstract][Full Text] [Related]
49. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma.
Kraus JA; Koopmann J; Kaskel P; Maintz D; Brandner S; Schramm J; Louis DN; Wiestler OD; von Deimling A
J Neuropathol Exp Neurol; 1995 Jan; 54(1):91-5. PubMed ID: 7815084
[TBL] [Abstract][Full Text] [Related]
50. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.
Felsberg J; Erkwoh A; Sabel MC; Kirsch L; Fimmers R; Blaschke B; Schlegel U; Schramm J; Wiestler OD; Reifenberger G
Brain Pathol; 2004 Apr; 14(2):121-30. PubMed ID: 15193024
[TBL] [Abstract][Full Text] [Related]
51. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.
von Deimling A; Louis DN; von Ammon K; Petersen I; Wiestler OD; Seizinger BR
Cancer Res; 1992 Aug; 52(15):4277-9. PubMed ID: 1353411
[TBL] [Abstract][Full Text] [Related]
52. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
53. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
Gadji M; Fortin D; Tsanaclis AM; Drouin R
Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
[TBL] [Abstract][Full Text] [Related]
54. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
[TBL] [Abstract][Full Text] [Related]
55. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
[TBL] [Abstract][Full Text] [Related]
56. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
[TBL] [Abstract][Full Text] [Related]
57. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
[TBL] [Abstract][Full Text] [Related]
58. Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH.
Talagas M; Marcorelles P; Uguen A; Redon S; Quintin-Roué I; Costa S; Férec C; Morel F; Hieu PD; De Braekeleer M
J Neurooncol; 2012 Sep; 109(2):405-13. PubMed ID: 22825724
[TBL] [Abstract][Full Text] [Related]
59. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
[TBL] [Abstract][Full Text] [Related]
60. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]